High materiality7/10
Kymera Therapeutics (KYMR) PT Raised to $170 at Guggenheim
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Guggenheim raises KYMR target to $170; price $118.15.
- KYMR: Target $170; price $118.15; Guggenheim.
Key facts
- 01
Target: $170
- 02
Posted price: $118.15
- 03
Analyst firm: Guggenheim
- 04
Analyst: Brad Canino
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.